secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001601485-25-000108
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio Q2 net loss $10.6M; IDMC positive for ELI-002 Phase 2; DFS readout Q4 2025
--------------------------------------------------------------------------------

- IDMC recommended continue ELI-002 Phase 2 pancreatic study without modification; final DFS analysis expected Q4 2025.
- Net loss $10.6M in Q2 2025 vs $7.2M in Q2 2024; R&D expense decreased to $7.0M.
- Cash $22.1M at June 30, 2025; secured $10M non-dilutive financing in Q2 2025.
- Company expects cash to fund operations into Q1 2026, beyond Phase 2 final analysis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148525000108/0001601485-25-000108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148525000108/angn-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001601485-25-000108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer